Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 236,400 shares, a decline of 9.6% from the March 15th total of 261,500 shares. Based on an average daily trading volume, of 88,300 shares, the days-to-cover ratio is currently 2.7 days.

Institutional Trading of Enlivex Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ENLV. Bank of America Corp DE grew its stake in shares of Enlivex Therapeutics by 87.0% in the first quarter. Bank of America Corp DE now owns 6,163 shares of the company’s stock worth $34,000 after purchasing an additional 2,867 shares during the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of Enlivex Therapeutics in the first quarter worth $68,000. UBS Group AG grew its stake in shares of Enlivex Therapeutics by 73.4% in the third quarter. UBS Group AG now owns 31,871 shares of the company’s stock worth $136,000 after purchasing an additional 13,490 shares during the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Enlivex Therapeutics by 89.6% in the first quarter. Jane Street Group LLC now owns 52,507 shares of the company’s stock worth $294,000 after purchasing an additional 24,807 shares during the last quarter. Institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Stock Performance

Shares of NASDAQ ENLV traded up $0.03 during midday trading on Wednesday, reaching $1.48. 388,662 shares of the company were exchanged, compared to its average volume of 167,805. The stock’s 50-day moving average price is $3.41 and its 200-day moving average price is $2.55. Enlivex Therapeutics has a one year low of $1.15 and a one year high of $4.59.

Analyst Ratings Changes

Separately, HC Wainwright decreased their target price on shares of Enlivex Therapeutics from $12.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, April 12th.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.